Reflections on the regulation of the Polypill.
Forslund
Lennart
L
Medical Information Unit, Medical Products Agency, Uppsala, Sweden. lennart.forslund@mpa.se
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control; D017277:Drug Approval; D004338:Drug Combinations; D005060:Europe; D005492:Folic Acid / Q000008:administration & dosage; D033161:Government Regulation; D006291:Health Policy; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006852:Hydrochlorothiazide; D005492:Folic Acid; D001241:Aspirin